top of page

Search Results

Search results for "Glaxo Inc"

Results found for "Glaxo Inc"

  • 📰 GPCR Weekly News, December 4 to 10, 2023

    The package includes four live Zoom sessions, a one-year Dr. drugmaker Cerevel Therapeutics for $8.7 billion FDA approves two gene therapies for sickle cell disease, including

  • Targeting Intracellular Allosteric Sites in GPCRs

    Allosteric ligands can be classified as positive allosteric modulators (PAMs), which increase the receptor G-protein-biased allosteric antagonists are under investigation for several GPCRs, including CCR2, CCR7

  • 📰 GPCR Weekly News, September 25 to October 1, 2023

    GPCR Activation and Signaling The non-nutritive sweetener sucralose increases β-arrestin signaling at

  • Nanobodies: New Dimensions in GPCR Signaling Research

    This allows for tailoring the half-life of nanobodies to increase their therapeutic window depending Nbs can stabilize specific conformations of proteins, including unstable structural intermediates and crystallization: Nanobodies can be used to stabilize the protomers of larger protein assemblies and increase Nb9-8: This nanobody was identified for the M2 muscarinic receptor (M2R) and increased the affinity of Nb39: This nanobody was identified for the μ-opioid receptor (μOR) and also increased the affinity of

  • 📰 GPCR Weekly News, September 4 to 10, 2023

    Adenosine Receptors in Cancer Cell Lines Severity of neurological long-COVID symptoms correlates with increased

  • Decoding β-Arrestins: from Structure to function

    Other techniques include nuclear magnetic resonance (NMR) spectroscopy for conformational dynamics analysis Emerging strategies incorporate unnatural amino acids and crosslinking for structural data inference This includes proteins like AP-2 and clathrin, vital for internalization, as well as MAPK cascade kinases isoforms interact distinctively with certain signaling kinases, emphasizing their role as hubs for increasing Pinpointing signaling pathways governed by β-arrestins, which exhibit increased or reduced activity within

  • 📰 GPCR Weekly News, July 24 to July 30, 2023

    GPCRs in Neuroscience Neuronal diversity of neuropeptide signaling, including galanin, in the mouse locus

  • 📰 GPCR Weekly News, July 17 to July 23, 2023

    Office decision to grant a patent for its proprietary immuno-oncology EP4 receptor antagonist program including

  • 📰 GPCR Weekly News, July 10 to 16, 2023

    Colorectal cancer incidence trends in Golestan, Iran: An age-period-cohort analysis 2004-2018.

  • 📰 GPCR Weekly News, June 26 to July 2, 2023

    Esophageal and gastric cancer incidence trends in Golestan, Iran: An age-period-cohort analysis 2004

  • Structural landscape of the Chemokine Receptor system

    Thanks to advancements in cryo-electron microscopy (cryo-EM) technology, there has been a rapid increase Additionally, other conserved binding features, including CRS1.5 and CRS3, have been identified. The N-terminal domains of CKRs has multiple sites for post-translational modifications, including tyrosine active states are facilitated by a "microswitch network" composed of conserved sequence motifs which include Recent advancements in cryo-EM technology have led to a rapid increase in the number of experimental

  • 📰 GPCR Weekly News, June 5 to 11, 2023

    Statin-induced increase in actin polymerization modulates GPCR dynamics and compartmentalization.

  • Unlocking Cell's Secrets: Spontaneous β-Arrestin-Membrane Preassociation Drives Receptor-Activation

    Transient interaction with the receptor catalyzes β-arrestin activation, including β-arrestin inter-domain The increase in active β-arrestin molecules and the time they spend diffusing on the plasma membrane

  • Artificial intelligence – faster, smarter, cheaper GPCR drug discovery

    Artificial intelligence in GPCR drug discovery The use of AI in GPCR drug discovery has increased over The models use a variety of data for the input, including amino acid sequences or structural data (from AI algorithms can integrate data from multiple sources, including genomics, proteomics, and pharmacological for GPCRs: AI can facilitate the development of personalized treatments by analyzing patient data, including The sharing and collaboration of data across academia, industry, and regulatory bodies will likely increase

  • VAMP2: a crucial player in the delivery of MOR to the synapse

    Several molecules from the SNARE complex, including vesicle-associated membrane protein 2 (VAMP2), regulate GPCR recycling, this process is complex and highly regulated that involves multiple molecular players, including

  • Feeder or trigger – CCR2 as a scavenger and regulator of cell migration

    internalization, with the same observations made for CCR2-expressing THP-1 monocytic cell line, together with an increase However, this scavenging role has been also described for several canonical chemokine receptors, including D’Amico et. al 2000), becoming incapable of promoting cell migration, a phenomenon which is likely to

  • 📰 GPCR Weekly News, March 13 to 19, 2023

    we can accommodate, so hurry and submit your poster so that we can add it to the list of posters and increase

  • 📰 GPCR Weekly News, March 6 to 12, 2023

    we can accommodate, so hurry and submit your poster so that we can add it to the list of posters and increase

  • 📰 GPCR Weekly News, February 27 to March 5, 2023

    we can accommodate, so hurry and submit your poster so that we can add it to the list of posters and increase

  • 📰 GPCR Weekly News, February 20 to 26, 2023

    If you'd like to suggest papers to include in our news, please email them to us at Hello@DrGPCR.com.

  • Regulators of G-protein signaling: essential players in GPCR signaling

    RGS proteins also contain a range of other structural motifs that are critical for their function, including revealed that the interaction between RGS proteins and GPCRs is mediated by a range of structural motifs, including RGS4 is expressed in various immune cells, including T cells and B cells, and has been shown to modulate dysregulation in disease: The Dysregulation of RGS proteins has been implicated in a range of diseases, including Relating to pain, RGS4 in pain regulation is a topic of increasing interest because it has been identified

  • 📰 GPCR Weekly News, February 13 to 19, 2023

    If you'd like to suggest papers to include in our news, please email them to us at Hello@DrGPCR.com.

  • Glyco-sulfo hotspots in the chemokine receptor system

    N-terminal PTMs include sulfation and glycosylation which contribute to the overall negative charge of Other examples of O-glycosylation impact on chemokine receptors include the viral receptor US28 (Bagdonaite This effect could be driven by a specific carrier or it can potentially be related with the increase

  • New role of β-arrestins in MOR signaling

    Some examples of opioids include heroin, morphine, codeine, fentanyl, methadone, tramadol and other opioid

  • Unlocking the Therapeutic Potential of Previously Undruggable GPCRs

    The significantly increased surface area of ligand-receptor interface for these GPCRs makes modulation These approaches include generating ligand analogs by precision engineering the natural small protein Right: Orion ligand analogs are engineered to optimize transmembrane domain providing significantly increased effective at killing cells than unconjugated MMAE, the Orion CCL5 superagonist analog significantly increased Available structural data across the GPCR superfamily is increasing at an exponential rate, alongside

  • Odorant receptors – a bit of smell for drug discovery

    Higher-resolution analysis of gene expression, including q)RT-PCR, microarray, or relatively new NGS (RNASeq) analyses, have indicated that OR genes are also expressed in non-olfactory tissues including expressed OR, whereas OR51E1 and OR51E2 represent ubiquitously expressed ORs, although there are highly increased Future directions Important directions in ORs research to advance drug discovery include the deorphanization

  • 📰 GPCR Weekly News

    Increased protease-activated receptor 1 autoantibodies are associated with severe COVID-19.

  • Overview of adhesion GPCRs self-activation

    Fortunately, the scientific community has become increasingly interested in studying these proteins and

  • Transmembrane domains of GPCR dimers – a novel hot spot for drug discovery

    GPCR dimers are therefore emerging drug targets in different therapeutic areas including depression,

  • Therapeutic validation of an orphan G protein‐coupled receptor

    of pro‐inflammatory disorders renders it a promising target in inflammatory and fibrotic conditions, including to study the function of this receptor towards clinical validation, as well as radiopharmaceuticals, including metabolite produced in vivo from indole‐3‐carbinol, which is present at high levels in some vegetables including GPR84 antagonists include a series of dihydropyrimidinoisoquinolinones (Labéguère et al., 2014), which

bottom of page